Alpine Immune Sciences Inc (NASDAQ:ALPN) shares, rose in value, with the stock price down by -1.19% to the previous day’s close as strong demand from buyers drove the stock to $34.91.
Actively observing the price movement in the last trading, the stock closed the session at $35.33. The value of beta (5-year monthly) was 1.13. Referring to stock’s 52-week performance, its high was $42.88, and the low was $6.71. On the whole, ALPN has fluctuated by -9.44% over the past month.
With the market capitalization of Alpine Immune Sciences Inc currently standing at about $2.29 billion, investors are eagerly awaiting this quarter’s results, scheduled for May 09, 2024 – May 13, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.42, which is expected to increase to -$0.3 for fiscal year -$1.69 and then to about -$1.91 by fiscal year 2025. Data indicates that the EPS growth is expected to be -164.10% in 2025, while the next year’s EPS growth is forecast to be -13.00%.
According to the average forecast, sales growth in current quarter could jump down -62.50%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $15.63 million, representing a decrease of -73.50% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that ALPN’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of ALPN currently trading nearly -7.69% and 5.07% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 44.86, while the 7-day volatility ratio is showing 7.60% which for the 30-day chart, stands at 6.86%. Furthermore, Alpine Immune Sciences Inc (ALPN)’s beta value is 1.19, and its average true range (ATR) is 2.46.
A comparison of Alpine Immune Sciences Inc (ALPN) with its peers suggests the former has fared considerably weaker in the market. ALPN showed an intraday change of -1.19% in last session, and over the past year, it grew by 363.61%%.
Data on historical trading for Alpine Immune Sciences Inc (NASDAQ:ALPN) indicates that the trading volumes over the past 10 days have averaged 1.13 million and over the past 3 months, they’ve averaged 1.18 million. According to company’s latest data on outstanding shares, there are 60.35 million shares outstanding.
Nearly 28.22% of Alpine Immune Sciences Inc’s shares belong to company insiders and institutional investors own 68.36% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.61 million shares as on Mar 15, 2024, resulting in a short ratio of 4.74. According to the data, the short interest in Alpine Immune Sciences Inc (ALPN) stood at 8.56% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 4.03 million. The stock has risen by 83.16% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ALPN stock heading into the next quarter.
